Welcome to our dedicated page for Cardiff Lexingto news (Ticker: CDIX), a resource for investors and traders seeking the latest updates and insights on Cardiff Lexingto stock.
Cardiff Lexington Corporation (OTCQB: CDIX) is a healthcare holding company focused on acquiring and building middle-market niche health care clinics in Orthopedics, Spine Care, and Pain Management. This news page aggregates company-issued updates and market-facing announcements that reflect how Cardiff Lexington and its Nova Ortho and Spine subsidiary are progressing operationally, financially, and strategically.
Readers can find earnings releases detailing quarterly and year-to-date financial performance, including revenue trends, gross profit, operating income, net loss, and non-GAAP measures such as adjusted EBITDA. These releases often discuss the impact of one-time non-cash adjustments, changes in interest expense related to the company’s line of credit, and enhancements to internal controls over financial reporting.
The news flow also includes corporate governance and leadership updates, such as the planned retirement of long-serving Chairman Daniel Thompson and the appointment of Chief Executive Officer Alex Cunningham as Chairman of the Board. Cardiff Lexington uses press releases to explain these changes and to describe how its leadership team is shaping strategy and operations.
Investors following CDIX can track capital markets developments through announcements about the company’s uplisting strategy, including the 1-for-3 reverse stock split intended to support Nasdaq Capital Market listing requirements and the filing of a Form S-1 registration statement. Additional releases highlight advisory relationships, such as the engagement of Greentree Financial Group to assist with governance, financial reporting, and public markets compliance.
Operationally, Cardiff Lexington’s news coverage features updates from Nova Ortho and Spine, including expansion into underserved and rural areas of Florida and the performance of procedures at partner hospitals. By reviewing this news feed, investors and observers can monitor Cardiff Lexington’s financial reporting schedule, conference call announcements, and ongoing efforts to grow its orthopedic, spine care, and pain management platform.
Cardiff Lexington (OTCQB:CDIX) has scheduled an investor conference call to discuss its Q2 2025 financial results on Tuesday, August 12, 2025, at 5:00 pm ET. The company will release its financial and operating results for the quarter ended June 30, 2025, before the call.
Investors can join via phone by dialing (877) 545-0523 (US) or (973) 528-0016 (International) using access code 674660. The call and slide deck will be available via webcast, with replay access until August 26, 2025.
Cardiff Lexington Corporation (OTCQB:CDIX) has successfully uplisted to the OTCQB Venture Market, effective May 15, 2025, while maintaining its "CDIX" ticker symbol. The uplisting follows a thorough verification process to ensure the company meets OTCQB listing requirements.
CEO Alex Cunningham highlighted this achievement as a significant milestone, emphasizing the company's commitment to transparency and shareholder value. The company reports being on track for a record 2025 and has made progress in streamlining its capital structure. The OTCQB listing, operated by OTC Markets Group and recognized by the SEC, is expected to enhance Cardiff Lexington's visibility with investors and support the expansion of its global shareholder base.
Cardiff Lexington (CDIX) reported strong financial results for Q1 2025, with total revenue increasing 26% year-over-year to $2.9 million. The company achieved significant growth in operating income, which rose 148% to $543,934. Gross profit increased 34% to $1.8 million, representing 63% of total revenue.
The company's expansion strategy, including opening several new Nova Ortho and Spine locations throughout Florida and the southeast US in 2024, has contributed to improved patient volume and service demand. As of March 31, 2025, Cardiff Lexington reported cash holdings of $996,758 and total assets of $25.3 million, marking a 6% increase. The company has also been working on streamlining its capital structure through the conversion of preferred shares to common stock.
Cardiff Lexington (CDIX) reported strong Q4 2024 financial results, with revenue increasing 31% to $3.1 million and gross profit reaching $2.0 million (65% margin). The company expanded its Nova Ortho and Spine footprint with two new locations in 2024: Valdosta, Georgia and Orlando, Florida.
Key financial highlights include a 37% increase in cash to $1.2 million, 15% increase in total assets to $23.9 million, and a significant 267% increase in shareholders' equity to $2.7 million. However, income from continuing operations decreased 20% to $332,147.
The company faced challenges in 2024, including Hurricane Helene disrupting Florida operations and $2.8 million in one-time non-cash adjustments. Non-GAAP adjusted revenue for 2024 was $11.1 million, with Q4 adjusted EBITDA increasing 20% to $579,370.
Cardiff Lexington (CDIX) reported Q3 2024 financial results, with total revenue of $1.36M, impacted by a one-time non-cash adjustment of $1.65M to align with claim settlement realization rates. Non-GAAP adjusted revenue was $3.01M. The company opened its 12th Nova Ortho and Spine location in Orlando, Florida, though severe weather delayed many procedures. The quarter saw increased costs, with cost of sales at $1M and SG&A expenses at $937K. Loss from continuing operations was $585K. Balance sheet highlights include a 125% increase in cash to $1.95M and a 410% increase in shareholders' equity to $3.73M.
Cardiff Lexington (OTC PINK:CDIX) has announced its financial results for Q2 and H1 2024. Key highlights include:
- Q2 revenue of $2,330,964 with a 66% gross profit margin
- H1 revenue of $4,992,930 with a 65% gross profit margin
- Shareholders' equity increased by 698% to $5,837,412
- Cash increased by 269% to $3,196,795
- Total assets increased by 19% to $24,659,020
The company reported a loss from continuing operations of $202,345 in Q2, partly due to increased bad debt expense. However, for H1, income from continuing operations was $16,647. Cardiff Lexington is focusing on expanding its healthcare locations, having opened its 12th Nova Ortho and Spine location in Orlando, Florida.
Cardiff Lexington (OTC Pink:CDIX) has announced the opening of its 12th Nova Ortho and Spine location in Orlando, Florida, set to open on August 5, 2024. This new 1,600 square foot facility marks the company's 11th location in Florida and establishes a presence in the state's fourth-largest city. Nova Ortho and Spine specializes in providing diagnostic and surgical services for traumatic injury victims, with revenue primarily derived from various insurance policies.
CEO Alex Cunningham emphasized that this expansion aligns with the company's growth strategy, enhancing visibility and patient access in larger metropolitan areas. Dr. Kevin Fitzgerald, Managing Director of Nova Ortho and Spine, highlighted the company's strong referral source and high patient satisfaction ratings as key factors in choosing Orlando for their newest location.
Cardiff Lexington (OTC PINK: CDIX) announced the cancellation of its Senior Secured Convertible Promissory Note, 8% Convertible Secured Redeemable Note, and series R preferred stock through an agreement with GHS Investments. In exchange, a new fixed amount settlement promissory note of $535,000 was issued, which bears no interest and requires fixed payments. CEO Alex Cunningham highlighted the elimination of convertible debt as a significant step towards simplifying and strengthening the company's capital structure. The company reported sequential revenue growth, a strong gross margin of 64% in Q1 2024, and a net income of $3 million for the full year 2023.
Cardiff Lexington (OTC Pink: CDIX) announced on June 11, 2024, the appointment of Shannon Vitale as controller and LaTanga Hickman as staff accountant to enhance its financial operations and support anticipated growth. Vitale brings over 15 years of experience in accounting and compliance, previously holding roles at Energy Focus and The NRP Group. Hickman, with over a decade of experience, has worked in various sectors including real estate and healthcare, most recently at Gas Xpress Development. The company aims to strengthen its finance team and drive strategic initiatives with these new additions. The role of chief accounting officer has been eliminated, and Zia Choe has left the company.
Cardiff Lexington (CDIX) reported a 12% sequential revenue growth in the first quarter of 2024, with a 64% gross profit margin. The operating income decreased due to scaling expenses and stock compensation, but excluding these, it showed a 48% sequential increase. The company is focused on strategic investments to support future growth and aims to uplist to a major U.S. exchange. With improved balance sheet metrics, Cardiff Lexington aims to expand its market presence and drive long-term growth.
FAQ
What is the current stock price of Cardiff Lexingto (CDIX)?
What is the market cap of Cardiff Lexingto (CDIX)?
